711 related articles for article (PubMed ID: 10088773)
1. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
[TBL] [Abstract][Full Text] [Related]
2. Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats.
Bendele A; Sennello G; McAbee T; Frazier J; Chlipala E; Rich B
J Rheumatol; 1999 Jun; 26(6):1225-9. PubMed ID: 10381034
[TBL] [Abstract][Full Text] [Related]
3. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.
Bendele AM; Chlipala ES; Scherrer J; Frazier J; Sennello G; Rich WJ; Edwards CK
Arthritis Rheum; 2000 Dec; 43(12):2648-59. PubMed ID: 11145022
[TBL] [Abstract][Full Text] [Related]
4. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
5. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy.
McComb J; Gould T; Chlipala E; Sennelo G; Frazier J; Kieft G; Seely J; Edwards CK; Bendele A
J Rheumatol; 1999 Jun; 26(6):1347-51. PubMed ID: 10381054
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
Jiang Y; Genant HK; Watt I; Cobby M; Bresnihan B; Aitchison R; McCabe D
Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
[TBL] [Abstract][Full Text] [Related]
7. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.
Joosten LA; Helsen MM; van de Loo FA; van den Berg WB
Arthritis Rheum; 2008 Feb; 58(2 Suppl):S110-22. PubMed ID: 18240201
[TBL] [Abstract][Full Text] [Related]
8. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
Gabay C; Marinova-Mutafchieva L; Williams RO; Gigley JP; Butler DM; Feldmann M; Arend WP
Arthritis Rheum; 2001 Feb; 44(2):451-62. PubMed ID: 11229477
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.
Hur W; Cho ML; Yoon SK; Kim SY; Ju JH; Jhun JY; Heo SB; Moon YM; Min SY; Park SH; Kim HY
Immunol Lett; 2006 Aug; 106(2):154-62. PubMed ID: 16793145
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit.
Arner EC; Harris RR; DiMeo TM; Collins RC; Galbraith W
J Rheumatol; 1995 Jul; 22(7):1338-46. PubMed ID: 7562769
[TBL] [Abstract][Full Text] [Related]
13. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
Schett G; Middleton S; Bolon B; Stolina M; Brown H; Zhu L; Pretorius J; Zack DJ; Kostenuik P; Feige U
Arthritis Rheum; 2005 May; 52(5):1604-11. PubMed ID: 15880601
[TBL] [Abstract][Full Text] [Related]
14. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
15. The effect of recombinant human interleukin 1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit.
Lewthwaite J; Blake SM; Hardingham TE; Warden PJ; Henderson B
J Rheumatol; 1994 Mar; 21(3):467-72. PubMed ID: 8006890
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247.
Maksymowych WP; Jhangri GS; Aspeslet L; Abel MD; Trepanier DJ; Naicker S; Freitag DG; Cooper BL; Foster RT; Yatscoff RW
J Rheumatol; 2002 Aug; 29(8):1646-52. PubMed ID: 12180723
[TBL] [Abstract][Full Text] [Related]
17. Arthritis in mice that are deficient in interleukin-1 receptor antagonist is dependent on genetic background.
Zhou F; He X; Iwakura Y; Horai R; Stuart JM
Arthritis Rheum; 2005 Dec; 52(12):3731-8. PubMed ID: 16320323
[TBL] [Abstract][Full Text] [Related]
18. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
Furst DE
Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist.
Lamacchia C; Palmer G; Seemayer CA; Talabot-Ayer D; Gabay C
Arthritis Rheum; 2010 Feb; 62(2):452-62. PubMed ID: 20112392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
